Omeros Corp
Closed
SectorHealthcare
9.27 -2.22
Overview
Share price change
24h
Min
9.1
Max
9.31
Income | -35M 51M |
|---|---|
Sales | 9.9M 9.9M |
P/E Sector Avg | 8.342 56.269 |
EPS | 0.977 |
Profit margin | 518.033 |
Employees | 175 |
EBITDA | 86M 57M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +255.6% upside |
Next Earnings | 13 Aug 2026 |
|---|
Market Cap | -348M 688M |
|---|---|
Previous open | 11.49 |
Previous close | 9.27 |
Omeros Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Omeros Corp Forecast
Price Target
By TipRanks
255.6% upside
12 Months Forecast
Average 33 USD 255.6%
High 33 USD
Low 33 USD
Based on 2 Wall Street analysts offering 12 month price targets forOmeros Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Omeros Corp
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
